Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Pharmacol Exp Ther
2008 Jun 01;3253:910-9. doi: 10.1124/jpet.108.136895.
Show Gene links
Show Anatomy links
Synthesis and characterization of 125I-alpha-conotoxin ArIB[V11L;V16A], a selective alpha7 nicotinic acetylcholine receptor antagonist.
Whiteaker P
,
Marks MJ
,
Christensen S
,
Dowell C
,
Collins AC
,
McIntosh JM
.
???displayArticle.abstract???
The alpha7 nicotinic acetylcholine receptors (nAChRs) are widely expressed both in the central nervous system (CNS) and periphery. In the CNS, 125I-alpha-bungarotoxin is commonly used to identify alpha7 nAChRs specifically. However, alpha-bungarotoxin also interacts potently with alpha1* and alpha9alpha10 nAChRs, two receptor subtypes in peripheral tissues that are colocalized with the alpha7 subtype. [3H]Methyllycaconitine is also frequently used as an alpha7-selective antagonist, but it has significant affinity for alpha6* and alpha9alpha10 nAChR subtypes. In this study, we have developed a highly alpha7-selective alpha-conotoxin radioligand by iodination of a naturally occurring histidine. Both mono- and diiodo derivatives were generated and purified (specific activities were 2200 and 4400 Ci mmol(-1), respectively). The properties of the mono- and diiodo derivatives were very similar to each other, but the diiodo was less stable. For monoidodo peptide, saturation binding to mouse hippocampal membranes demonstrated a K(d) value of 1.15 +/- 0.13 nM, similar to that of 125I-alpha-bungarotoxin in the same preparations (0.52 +/- 0.16 nM). Association and dissociation kinetics were relatively rapid (k(obs) for association at 1 nM was 0.027 +/- 0.007 min(-1); k(off) = 0.020 +/- 0.001 min(-1)). Selectivity was confirmed with autoradiography using alpha7-null mutant tissue: specific binding was abolished in all regions of alpha7(-/-) brains, whereas wild-type mice expressed high levels of labeling and low nonspecific binding. 125I-alpha-conotoxin ArIB[V11L; V16A] should prove useful where alpha7 nAChRs are coexpressed with other subtypes that are also labeled by existing ligands. Furthermore, true equilibrium binding experiments could be performed on alpha7 nAChRs, something that is impossible with 125I-alpha-bungarotoxin.
Baker,
Pharmacological properties of alpha 9 alpha 10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras.
2004, Pubmed,
Xenbase
Baker,
Pharmacological properties of alpha 9 alpha 10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras.
2004,
Pubmed
,
Xenbase
Changeux,
Use of a snake venom toxin to characterize the cholinergic receptor protein.
1970,
Pubmed
Chen,
The alpha-bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the alpha7 subunit.
1997,
Pubmed
,
Xenbase
Clarke,
The fall and rise of neuronal alpha-bungarotoxin binding proteins.
1992,
Pubmed
Clarke,
Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin.
1985,
Pubmed
Davies,
Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors.
1999,
Pubmed
Elgoyhen,
alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells.
2001,
Pubmed
,
Xenbase
Franceschini,
Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures.
2002,
Pubmed
Gotti,
Pharmacology and biophysical properties of alpha 7 and alpha 7-alpha 8 alpha-bungarotoxin receptor subtypes immunopurified from the chick optic lobe.
1994,
Pubmed
,
Xenbase
Gotti,
Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion.
2005,
Pubmed
Haberberger,
Nicotinic acetylcholine receptor subtypes in nociceptive dorsal root ganglion neurons of the adult rat.
2004,
Pubmed
Marks,
Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain.
1998,
Pubmed
Martyn,
Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms.
2006,
Pubmed
Morley,
Identification of the subunits of the nicotinic cholinergic receptors in the rat cochlea using RT-PCR and in situ hybridization.
1998,
Pubmed
Nguyen,
Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity.
2000,
Pubmed
Parker,
Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.
1998,
Pubmed
,
Xenbase
Pauly,
An autoradiographic analysis of cholinergic receptors in mouse brain.
1989,
Pubmed
Peng,
Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes.
2004,
Pubmed
Pérez Maceda,
[125I]diiodoinsulins. Binding affinities, biologic potencies, and properties of their decay products.
1982,
Pubmed
Quik,
Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.
2003,
Pubmed
Salminen,
The subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay.
2005,
Pubmed
Salvaterra,
Nicotinic acetylcholine receptor from rat brain. Solubilization, partial purification, and characterization.
1976,
Pubmed
Whiteaker,
Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist.
2007,
Pubmed
,
Xenbase
Whiteaker,
Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine.
2000,
Pubmed
Whiteaker,
125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain.
2000,
Pubmed
